Skip to main content

Advertisement

SpringerLink
Log in

Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the therapeutic outcome for dexamethasone implant (DEX) or intravitreal ranibizumab (IVR) injections over 6 months in patients with macular edema due to branch or central retinal vein occlusion (BRVO, CRVO), in a real-life setting.

Methods

A total of 107 patients with BRVO or CRVO were included into this retrospective single-center observational study. Patients were treated with monotherapy consisting of DEX or three monthly IVR injections following a pro re nata regimen (PRN). Best-corrected visual acuity (BCVA), central retinal thickness (CRT) and intraocular pressure (IOP) were compared between the two therapy groups after 1, 3 and 6 months.

Results

BRVO patients treated with DEX achieved a statistically significant gain in BCVA measured in logMAR after 1 month (mean gain, 95% CI: 0.21, 0.08–0.34, p = 0.001), 3 months (0.16, 0.03–0.28, p = 0.012) and 6 months (0.19, 0.07–0.32, p = 0.002), whereas patients treated with IVR showed a statistically significant BCVA gain in month 3 (mean improvement, 95% CI: 0.13, 0.01–0.26, p = 0.039) and month 6 (0.16, 0.03–0.29, p = 0.018). BCVA in CRVO patients with DEX worsened slightly at month 6 (mean worsening, 95% CI: −0.08, −0.24 to 0.08, p = 0.305), while IVR treated-patients achieved a statistically significant BCVA gain at 3 months (mean improvement, 95% CI: 0.14, 0.02–0.25, p = 0.021). Both therapies were accompanied by statistically significant CRT reductions of 150 to 200 μm (median). Adverse events reported were predictable and limited.

Conclusions

In a clinical setting, comparable improvement in BCVA and CRT were observed after DEX and IVR injections for treatment of BRVO. CRVO patients showed greater benefit with IVR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jarques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham- controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146

    Article  PubMed  Google Scholar 

  2. Campochiaro PA, Heier JS, Feiner L (2010) Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112

    Article  PubMed  Google Scholar 

  3. Brown DM, Campochiaro PA, Singh RP (2010) Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133

    Article  PubMed  Google Scholar 

  4. Winterhalter S, vom Brocke GA, Klamann MK, Müller B, Joussen AM (2015) Monthly microperimetry (MP1) measurement of macular sensitivity after dexamethasone implantation (Ozurdex) in retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol 253(11):1873–1882

    Article  CAS  PubMed  Google Scholar 

  5. Mathew R, Pearce E, Muniraju R, Abdul-Hey A, Sivaprasad S (2014) Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME report 1). Eye 28(3):318–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F (2013) Repeated intravitreal dexamethasone implant (Ozurdex) for retinal vein occlusion. Ophthalmologica 229(1):21–25

    Article  CAS  PubMed  Google Scholar 

  7. Augustin AJ, Holz FG, Haritoglou C, Mayer WJ, Bopp S, Scheuerle AF, Maier M, Sekundo W, Sandner D, Shirlaw A, Hattenbach LO (2015) Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica 233:18–26. https://doi.org/10.1159/000368840

    Article  CAS  PubMed  Google Scholar 

  8. Hattenbach LO, Feltgen N, Bertelmann T et al (2017) Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol. https://doi.org/10.1111/aos.13381

  9. Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO, COMRADE-C Study Group (2016) Clinical efficacy and safety of Ranibizumab versus Dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Opthamol. https://doi.org/10.1016/j.ajo.2016.06.016

  10. IVAN Study Investigators, Chakravarthy U, Harding SP et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411

    Article  Google Scholar 

  11. Lotery AJ, Gibson J, Cree AJ et al (2013) Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN study. Ophthalmology 120:2637–2643

    Article  PubMed  Google Scholar 

  12. Bach M, Kommerell G (1998) Determining visual acuity using European normal values: scientific principles and possibilities for automatic measurement. Klin Monatsbl Augenheilkd 212(4):190–195

    Article  CAS  PubMed  Google Scholar 

  13. Sugrue MF (1996) The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 12(3):363–376

    Article  CAS  PubMed  Google Scholar 

  14. Park HY, Lee NY, Kim JH et al (2008) Intraocular pressure lowering, change of antiapoptotic molecule expression, and neuroretinal changes by dorzolamide 2%/timolol 0.5% combination in a chronic ocular hypertension rat model. J Ocul Pharmacol Ther 24(6):563–571

    Article  CAS  PubMed  Google Scholar 

  15. Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/ hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31(2):78–86

    Article  PubMed  Google Scholar 

  16. Mayer WJ, Haritoglou A, Wolf A et al (2015) Comparison of Intravitreal Dexamethasone implant versus Intravitreal Ranibizumab as a first-line treatment of macular Oedema due to retinal vein occlusion. Klin Monatsbl Augenheilkd 232(11):1289–1296

    Article  CAS  PubMed  Google Scholar 

  17. Chiquet C, Dupuy C, Bron AM et al (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol 253(12):2095–2102

    Article  CAS  PubMed  Google Scholar 

  18. Yumusak E, Buyuktortop N, Ornek K (2016) Early results of dexamethasone implant, ranibizumab, and triamcinolone in macular edema due to branch retinal vein occlusion. Eur J Ophthalmol 26(1):54–59

    Article  PubMed  Google Scholar 

  19. Eter N, Mohr A, Wachtlin J et al (2016) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicentre clinical trial. Graefes Arch Clin Exp Ophthalmol 255(1):77–87

    Article  PubMed  PubMed Central  Google Scholar 

  20. Korobelnik JF, Kodjikian L, Delcour C et al (2016) Two-year, prospective, multicentre study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 254(12):2307–2318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bezatis A, Spital G, Höhn F et al (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up – the SOLO study. Acta Ophthalmol 91(5):e340–e347

    Article  PubMed  Google Scholar 

  22. Capone A Jr, Singer MA, Dodwell DG et al (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 34(2):342–351

    Article  CAS  PubMed  Google Scholar 

  23. Lip PL, Malick H, Damer K et al (2015) One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK. Clin Ophthalmol 25(9):1779–1784

    Article  Google Scholar 

  24. Narayanan R, Panchal B, Das T et al (2015) A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report no.1. Br J Ophthalmol 99(7):954–959

    Article  PubMed  Google Scholar 

  25. Larsen M, Waldstein SM, Boscia F et al (2016) Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123(5):1101–1111

    Article  PubMed  Google Scholar 

  26. Farinha C, Marques JP, Almeida E et al (2015) Treatment of retinal vein occlusion with Ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res 55(1):10–18

    Article  PubMed  Google Scholar 

  27. Campochiaro PA, Sophie R, Pearlman J et al (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121(1):209–219

    Article  PubMed  Google Scholar 

  28. Brynskov T, Kemp H, Sørensen TL (2014) Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice. Retina 34(8):1637–1643

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr. Patricia Buchholz for her advice.

Author information

Author notes

  1. Sibylle Winterhalter and Annabelle Eckert contributed equally to this work.

Authors and Affiliations

  1. Department of Ophthalmology, Campus Virchow-Klinikum, Charité – University Medicine Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany

    Sibylle Winterhalter, Annabelle Eckert, Gerrit-Alexander vom Brocke, Dominika Pohlmann, Daniel Pilger, Antonia M. Joussen & Matus Rehak

  2. Ophthalmicus Augentagesklinik, Villingen-Schwenningen, Germany

    Annabelle Eckert

  3. Department of Biostatistics and Clinical Epidemiology, Charité – University Medicine Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany

    Alice Schneider & Ulrike Grittner

  4. Department of Ophthalmology, Universitätsklinikum Leipzig, Leipzig, Germany

    Matus Rehak

Authors
  1. Sibylle Winterhalter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annabelle Eckert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerrit-Alexander vom Brocke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alice Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dominika Pohlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniel Pilger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonia M. Joussen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Matus Rehak
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ulrike Grittner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sibylle Winterhalter.

Ethics declarations

For this type of study, formal consent is not required.

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Winterhalter, S., Eckert, A., vom Brocke, GA. et al. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. Graefes Arch Clin Exp Ophthalmol 256, 267–279 (2018). https://doi.org/10.1007/s00417-017-3852-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-017-3852-1

Keywords

Search

Navigation